BCRX
BioCryst Pharmaceuticals, Inc. (BCRX) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosures or incidents were provided in the fresh data.
Capital intensity remains low, with capexToRevenueTTM at 0.29% and capexToOperatingCashFlowTTM at 0.77%.
Social
No material social metrics or workforce/community disclosures were provided in the fresh data.
Stock-based compensation remains meaningful at 12.96% of revenue, which can dilute stakeholders if not offset by growth.
Governance
No material governance news or policy changes were provided in the fresh data.
Liquidity remains solid with a current ratio of 2.32 and cash ratio of 0.74, while leverage appears manageable on a net basis with netDebtToEBITDATTM at -0.84.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on BioCryst Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.